🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are escalating globally, with estimates suggesting more than 82 million infections each year. Especially elevated rates are seen in Africa and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an important and timely development in the face of rising global incidence, escalating drug resistance and the extremely scarce therapeutic options at this time.”

Health officials are deeply concerned about the rise in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". Ongoing monitoring revealed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Receive Approval

Zoliflodacin, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This medication, which is also used to treat UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This milestone signifies a significant shift in the management of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Outcomes and Global Access

According to data published in a prominent scientific publication, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which uses an injection and a pill. The research included nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the ability to register and commercialise the drug in many low-income and middle-income countries.

Medical professionals directly involved have expressed hope. Access to a one-pill regimen of this kind is described as a "game-changer" for managing the epidemic. This is viewed as crucial to alleviate the strain of the infection for individuals and to stop the proliferation of extremely resistant gonorrhoea around the world.